Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.

SHSE:600613 Stock Report

Market Cap: CN¥3.5b

Shanghai Shenqi Pharmaceutical Investment Management Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Feng Bin

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure12.9yrs
CEO ownershipn/a
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Why Shanghai Shenqi Pharmaceutical Investment Management's (SHSE:600613) Earnings Are Better Than They Seem

May 06
Why Shanghai Shenqi Pharmaceutical Investment Management's (SHSE:600613) Earnings Are Better Than They Seem

Investor Optimism Abounds Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHSE:600613) But Growth Is Lacking

Apr 17
Investor Optimism Abounds Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHSE:600613) But Growth Is Lacking

CEO

Feng Bin (49 yo)

12.9yrs

Tenure

CN¥451,700

Compensation

Mr. Feng Bin is the Managing Director and Director of Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd. (formerly known as Shanghai Wingsung Investment Management Co., Ltd.) and served as its...


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.